ArticleClinical kidney journal2022

C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study.

Annette Bruchfeld et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.